P1211: TUMOR-ACTIVATED LYMPH NODE FIBROBLASTS SUPPRESS T CELL FUNCTION IN DIFFUSE LARGE B CELL LYMPHOMA by Benedetta Apollonio, Filomena Spada, Nedyalko Petrov, Domenico Cozzetto, Peter Jarvis, Despoina Papazoglou, Shichina Kannambath, Manuela Terranova-Barberio, Rose-Marie Amini, Gunilla Enblad, Charlotte Graham, Reuben Benjamin, Elizabeth H. Phillips, Richard Ellis, Rosamond Nuamah, Mansoor Saqi, Dinis Calado, Richard Rosenquist, Lesley Ann Sutton, Jon Salisbury, Georgios Zacharioudakis, Anna Vardi, Patrick Hagner, Anita Gandhi, Marina Bacac, Christina Claus, Pablo Umana, Ruth Jarrett, Christian Klein, Alexander Deutsch, Alan Ramsay

Get full text

PO.6.137 Design of a phase 2, multicenter, randomized, placebo-controlled, parallel-group, double-blind study to assess the efficacy and safety of nipocalimab in adults with active... by T Rooney, R Gordon, G Vratsanos, C Calderon, S Gao, RW Hoffman, F Zazzetti, F Liu-Walsh, B Van Hartingsveldt, Q Zuraw, JH Leu, A Berhanu Debella

1465 Multiplex imaging identifies unique immunophenotypic and spatial characteristics associated with response to immune checkpoint inhibitors (ICIs) in metastatic urothelial cance... by Padmanee Sharma, Seunghee Kim-Schulze, Justin David, John-William Sidhom, Sacha Gnjatic, Guray Akturk, Matthew Galsky, Saurabh Gupta, Jonathan Anker, Sudeh Izadmehr

Meeting Report of the 33rd Annual Meeting of the Academy of Surgical Research: Summary of Presentations, Labs, and Workshops, Focusing on Experimental Surgery, Las Vegas, NV, Octob... by Melanie L. Graham, Tracy Ziegelhofer, Jon Ehrmann

Get full text

Rapid, direct, and sensitive determination of aziridine and 2-chloroethylamine by hydrophilic interaction liquid chromatography-mass spectrometry by Jonathan G. Shackman

Get full text

Taxanes in the elderly patient with metastatic breast cancer [Corrigendum] by Yardley DA

“…Dr Yardley reports grants to her institution, Sarah Cannon Research Institute, for studies on which she served as Principal Investigator, outside of the submitted work, from the following companies: Novartis, Janssen, Roche/Genentech, Bristol-Myers Squibb, Amgen, Celgene, Eli Lilly, GlaxoSmithKline, Medimmune, Medivation, Pfizer, Sanofi, Tesaro, Eisai, AbbVie, Astellas, Biomarin, Celldex, Clovis, Incyte, Merrimack, Imclone, Luitpold, Macrogenics, and Veridex. …”
Get full text

Reversible Myc hypomorphism identifies a key Myc-dependency in early cancer evolution by Nicole M. Sodir, Luca Pellegrinet, Roderik M. Kortlever, Tania Campos, Yong-Won Kwon, Shinseog Kim, Daniel Garcia, Alessandra Perfetto, Panayiotis Anastasiou, Lamorna Brown Swigart, Mark J. Arends, Trevor D. Littlewood, Gerard I. Evan

Get full text

Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review. by Juszczak, A, Gupta, A, Karavitaki, N, Middleton, MR, Grossman, AB

“…Ipilimumab (Yervoy; Medarex and Bristol-Myers Squibb) is a human MAB against cytotoxic T-lymphocyte antigen 4, which enhances co-stimulation of cytotoxic T-lymphocytes, resulting in their proliferation and an anti-tumour response. …”

Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial by Elizabeth A. Brown, Anne Minnich, Arun J. Sanyal, Rohit Loomba, Shuyan Du, John Schwarz, Richard L. Ehman, Morten Karsdal, Diana J. Leeming, Giovanni Cizza, Edgar D. Charles

Get full text

IL22 Inhibits Epithelial Stem Cell Expansion in an Ileal Organoid ModelSummary by Bailey Zwarycz, Adam D. Gracz, Kristina R. Rivera, Ian A. Williamson, Leigh A. Samsa, Josh Starmer, Michael A. Daniele, Luisa Salter-Cid, Qihong Zhao, Scott T. Magness

Get full text

Investigating the feasibility of recruitment to an observational, quality-of-life study of patients diagnosed with atrial fibrillation (AF) who have experienced a bleed while antic... by Hayley A. Hutchings, Kirsty Lanyon, Steven Lister, Raza Alikhan, Julian Halcox, Gail Holland, Arfon Hughes, Rhys Jenkins, Hamish Laing, Trudie Lobban, Diane Owen, Kevin G. Pollock, Ceri Todd, Kathie Wareham

Get full text

Preferences for Renal Cell Carcinoma Pharmacological Treatment: A Discrete Choice Experiment in Patients and Oncologists by Ovidio Fernández, Martín Lázaro-Quintela, Martín Lázaro-Quintela, Guillermo Crespo, Diego Soto de Prado, Álvaro Pinto, Laura Basterretxea, Alfonso Gómez de Liaño, Olatz Etxaniz, Sara Blasco, Clara Gabás-Rivera, Susana Aceituno, Virginia Palomar, Carlos Polanco-Sánchez

Get full text

Short-Term Hemodynamic Effects of Apelin in Patients With Pulmonary Arterial Hypertension by Lauren Brash, MD, Gareth D. Barnes, MD, Melanie J. Brewis, MD, A. Colin Church, MD, Simon J. Gibbs, MD, Luke S.G.E. Howard, MD, Geeshath Jayasekera, MBChB, Martin K. Johnson, MD, Neil McGlinchey, MBChB, Joelle Onorato, PhD, Joanne Simpson, MD, Colin Stirrat, MD, Stephen Thomson, MBChB, Geoffrey Watson, MD, Martin R. Wilkins, MD, Carrie Xu, MS, David J. Welsh, PhD, David E. Newby, MD, Andrew J. Peacock, MD

Get full text

Meeting Report of the 34th Annual Meeting of the Academy of Surgical Research: Summary of Presentations, Labs, and Workshops, Focusing on Experimental Surgery, Charleston, SC, Sept... by Melanie L. Graham, Leslie J. Stoll, Jon Ehrmann

Get full text

Access to hepatitis C medicines by Danny J Edwards, Delphi GM Coppens, Tara L Prasad, Laurien A Rook, Jayasree K Iyer

“…Six of these companies are developing medicines for hepatitis C: AbbVie, Bristol-Myers Squibb, Gilead, Johnson & Johnson, Merck & Co. and Roche. …”
Get full text

Efficacy and Safety of Antithrombotic Therapy in Patients With Atrial Fibrillation, Recent Acute Coronary Syndrome, or Percutaneous Coronary Intervention and a History of Heart Fai... by Marat Fudim, Daniel M. Wojdyla, John H. Alexander, Shaun G. Goodman, Roxana Mehran, Stephan Windecker, Ronald Aronson, Dragos Vinereanu, Sigrun Halvorsen, M. Cecilia Bahit, Christopher B. Granger, Renato D. Lopes

Get full text

Cytotoxic Effect of Nefazodone on HepG2 Cell Line and the Reliability of Comet Assay to Determine Genotoxicity. by Mustafa Tariq Sakin, Yassir Mustafa Kamal

“… Nefazodone is atypical antidepressant which was manufactured by Bristol-Myers Squibb in 1994 to avoid the adverse effects associated with other antidepressants, including nausea, sedation, insomnia, cardiovascular toxi-city, weight gain and dysfunction. …”
Get full text

Design and conduct considerations for studies in patients with hepatic impairment by Paulien Ravenstijn, Manoranjenni Chetty, Pooja Manchandani, Mohamed Elmeliegy, Hisham Qosa, Islam Younis

Get full text

Special Convening and Listening Session on Health Equity and Community Outreach and Engagement at National Cancer Institute-Designated Comprehensive Cancer Centers

“…To do so, the Bristol Myers Squibb Foundation (BMSF) hosted a special convening and listening session in April 2019. …”
Get full text

Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer by Marta Vallee Cobham, Diana Donovan

“…Marta Vallee Cobham, Diana DonovanWeill Cornell Breast Center, Cornell University/New York-Presbyterian Hospital, New York, NY, USAAbstract: Ixabepilone (Ixempra®; Bristol-Myers Squibb) is a novel microtubule stabilizing agent recently approved for the treatment of metastatic breast cancer (MBC). …”
Get full text